Interview: Lupin set for Latin American buy as it expands internationally
This article was originally published in Scrip
Executive Summary
Nilesh Gupta, Lupin's group president, is refreshingly candid and quite at ease to admit that the company may have missed some interesting business opportunities in the past. He even notes that some of the views he's shared with Scrip may not look very good in print.
You may also be interested in...
WHO No-Go Not A Swan Song For Remdesivir In India?
The WHO’s new "living guideline" against remdesivir’s use in hospitalized patients notwithstanding, some key opinion leaders in India see a role for the antiviral, but underscore that COVID-19 is still in its infancy and all repurposed therapies for the disease still have a long way to go. They also see the US remdesivir studies as more robust.
Novartis Faces Another Challenge To Entresto In India
More patent-related turbulence appears ahead for Novartis’s sacubitril/valsartan combination in India, with Torrent emerging as the new challenger. The companies are engaged in a legal battle and the Indian firm is also seeking a revocation of the patent on the star heart failure treatment.
India-China Tango: Can Gland Sustain Listing Luster?
Gland Pharma, controlled by Chinese group Fosun, makes shining debut on Indian stock markets despite a lukewarm response to its IPO. Will the buoyant market sentiment sustain amid edgy India-China relations?
Need a specific report? 1000+ reports available
Buy Reports